Strategic use of disease-modifying therapies following autologous stem cell transplantation in multiple sclerosis: A real-world evidence-based review

Anna Belenciuc; Alexandru Grumeza; Vitalie Lisnic

doi:10.1016/j.jns.2025.124249

December 1, 2025Journal of the Neurological Sciences

Strategic use of disease-modifying therapies following autologous stem cell transplantation in multiple sclerosis: A real-world evidence-based review

View at Publisher

Ask AI

Bookmark

Share

Key Points

Disease-modifying therapies improve outcomes following autologous stem cell transplantation in multiple sclerosis.
The review assesses various strategies and their effects on patients with multiple sclerosis, showcasing significant benefits.
Assessment of treatment protocols reveals a need for optimized clinical applications in multiple sclerosis management.
Findings suggest integrating disease-modifying therapies could enhance long-term quality of life and therapeutic effectiveness.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Real-world evidence highlights the impact of disease-modifying therapies after stem cell transplantation in multiple sclerosis, emphasizing treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Belenciuc et al. (2025) studied this question.

synapsesocial.com/papers/69a75f55c6e9836116a2aa33 https://doi.org/10.1016/j.jns.2025.124249

View at Publisher

Ask AI

Bookmark

Share

Strategic use of disease-modifying therapies following autologous stem cell transplantation in multiple sclerosis: A real-world evidence-based review

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Strategic use of disease-modifying therapies following autologous stem cell transplantation in multiple sclerosis: A real-world evidence-based review

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading